DBV Technologies (FR:DBV)
:DBV
Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€3.62
€0.10(13.73%)
At close: 4:00 PM EST
€3.62
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.30 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€902.81M
Enterprise Value€439.45M
Total Cash (Recent Filing)€229.20M
Total Debt (Recent Filing)€6.10M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Jul 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding296,061,500
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside-10.08% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.70M
Bulls Say, Bears Say
Bulls Say
Proprietary EPIT PlatformDBV’s Viaskin EPIT is a platform technology that delivers allergens via the skin, creating a durable competitive asset. As a platform, it can be extended to multiple allergens or indications, supporting scalable long-term pipelines, licensing and partner commercialization opportunities if clinical success is achieved.
Low Leverage And Sizeable Asset BaseThe company’s very low debt ratio and meaningful asset base provide financial flexibility to fund clinical programs and negotiate partnerships without immediate leverage pressure. This reduces near-term solvency risk and supports strategic options like licensing or staged financing to preserve operations over months.
Addressable Structural Market (food Allergies)DBV targets a structural, underserved therapeutic area—food allergy treatment—where approved, disease-modifying therapies are limited. If Viaskin demonstrates durable clinical benefit, sustained demand and payer interest could create a long-term commercial opportunity and enduring revenue runway across allergens.
Bears Say
Zero TTM Revenue And Large LossesThe company currently generates no recurring product revenue and reports material operating losses, indicating it remains pre-commercial. Persistent negative earnings erode equity and require external funding or a successful commercial launch to reverse, creating sustained execution and financing risk.
Sustained Cash Burn / Negative Free Cash FlowOperating losses are translating into real cash outflows, producing large negative operating and free cash flow. Continued burn increases the probability of dilutive capital raises or partnership deals under non-ideal terms, pressuring long-term shareholder value absent near-term clinical or regulatory inflection.
Dependence On External Financing And ApprovalsDBV’s business model lacks current commercial revenue and relies on financing, milestones or partnerships to fund operations. This structural dependence ties company viability to trial and regulatory success and capital markets access, making execution risk and dilution persistent risks over the coming months.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.30 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €902.81M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Jul 29, 2026 which is in 55 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Apr 30, 2026. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.023 by €0.004.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 296,061,500 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€3.26
▼(-10.08% Downside)
Technical Analysis
Options Prices
Currently, No data available
---